📌Advances in targeted therapies
✨ ADC 🔛🎙️ @kevinpunie.bsky.social
@oncoalert.bsky.social #OncoAlertAF #EBCC15

📌 Advances in targeted therapies
Excellent presentation on CDK4/6 ✨ by prof Nadia Harbeck ✨at #EBCC15 @oncoalert.bsky.social #OncoAlertAF

📌Advances in targeted therapies
✨Beyond Her2+ ✨ led by
@tomaspascualmd.bsky.social #EBCC15
@oncoalert.bsky.social #OncoAlertAF

Our #OncoAlertAF 🚨Colleague Nicholas Hornstein 🇺🇸 of @NorthwellHealth with TOP picks of #GIOncology Presented at #ESMO25 🇩🇪 👉 youtu.be/tVaVJ7pg50I

for the OncoAlert TOP3 Series post ESMO 2025, more to come..

✅NICHE2
✅STELLAR 303

📌 Primary Results From ASCENT-03 ✨

PFS: 9.7 mo vs 6.9 mo, HR 0.62
ORR: 48% vs 46%
DOR: 12.2 vs 7.2 mo
OS immature: HR 0.98
PFS2: 18.2 vs 14.0, HR 0.70

Dr. @Javier Cortès at Proffered paper session 2
#ESMO25 🇩🇪 📍Berlin
@oncoalert.bsky.social #OncoalertAF @nejm.org
🔗 lnkd.in/diBhSjXG

📌 Primary results from the randomised, phase III TROPION-Breast02 trial✨

🔸OS HR 0.79 (95% Cl 0.64-0.98); P=0.0291
🔹PFS by BICR HR 0.57 (95% CI 0.47-0.69); Р<0.0001
🔸 ≥5-month improvement in both median OS and PFS

Proffered paper session 2

#ESMO25 @oncoalert.bsky.social #OncoalertAF

💥 Practice changing #SCLC ❗

📌 DeLLphi-304
Tarlatamab vs ChT 2L ED SCLC

✅ mOS 13.6 vs 8.3m
✅ mPFS 5.3 vs 4.3m
✅ ORR 35 vs 20%
☣️ =>G3 54 vs 80%
⚠️ Watch #CRS 56% and #ICAN for Tarla
🧠 45% brain M1

@oncoalert.bsky.social
@ascocancer.bsky.social
@myesmo.bsky.social
#OncoAlertAF

✍🏽 June 2👇🏽

📌 Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

🔗nejm.org/doi/full/10.10…

👉🏻 Results of NRG-NSABP B-51/RTOG 1304❗️ RNI vs no RNI in ypN0 after neoadjuvant chemo (cT1-T3N1)

@oncoalert.bsky.social #OncoAlertAF #BreastCancer #RadOnc

📌 Opting Out of Therapy for Early-Stage Breast Cancer: How Far Might We Go?
✨Prof @icromeattini.bsky.social
👉🏻 How to Integrate Radiotherapy Into Current Treatment Concepts❗️
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #RadOnc

📌 NRG-BR003: A randomized phase Ill trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative
TNBC.
✨Vicente Valero #ASCO25
@oncoalert.bsky.social #OncoAlertAF

📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer.
✨Erica L. Mayer, MD, MPH, FASCO
✔️Rapid Oral Abstract Session
Breast Cancer-Local/Regional/ Adjuvant
@oncoalert.bsky.social #OncoAlertAF #ASCO25 #Day3

📌 Highlights of the Day II
👉🏻Breast Cancer-Metastatic
✨@maryam_lustberg 👏🏻
🟩 Key takeaways HR+ MBC
🟦 Key takeaways in HER2 positive MBC
🟨 Key Takeaways Metastatic TNBC
@oncoalert.bsky.social #OncoAlertAF #ASCO25

📌 Do We "Node" What to Do About the Axilla❓
Great discussion👏🏻
✨Mediget Teshome, MD, FACS, MPH
@oncoalert.bsky.social #OncoAlertAF #ASCO25

📌 LBA Session❗️
✨DESTINY-Breast09 results ✅
Stunning presentation ✨ @stolaney1.bsky.social 👏🏻

👉🏻 Median PFS:
🔸T-DXd + P: 40.7 mo
🔸THP: 26.9 mo
HR 0.56, p<0.001
👉🏻ORR 85.1%

@oncoalert.bsky.social #OncoAlertAF #ASCO25

📌Proud to share our latest review: “Current Treatment Paradigms for Advanced Melanoma with Brain Metastases” 🧠

mdpi.com/1422-0067/26/8…

👉🏻 Optimizing local & systemic strategies, tackling key clinical questions, and paving the way for tailored therapies.
@oncoalert.bsky.social #OncoAlertAF

📌 Awareness of genomic testing among patients with breast cancer in Europe 🧬

www.sciencedirect.com/science/arti...

@oncoalert.bsky.social #OncoAlertAF @breastdocuk.bsky.social
@csabadegi.bsky.social

📌 Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
@oncoalert.bsky.social #OncoAlertAF

thegreenjournal.com/article/S0167-…

📌 Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation

sciencedirect.com/science/articl…
@oncoalert.bsky.social #OncoAlertAF

📌 Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery

@oncoalert.bsky.social #OncoAlertAF @ijrobp.bsky.social #BreastCancer

📌 Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial

nature.com/articles/s4159…
@oncoalert.bsky.social #OncoAlertAF

📌 Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

ejcancer.com/article/S0959-…
@oncoalert.bsky.social #OncoAlertAF

📌 ESTRO guidelines for developing questionnaires in survey-based radiation oncology research

ctro.science/article/S2405-…
@oncoalert.bsky.social #OncoAlertAF #RadOnc

📌 Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
@nejm.org
nejm.org/doi/full/10.10…
The Katherine phase III updated results

@oncoalert.bsky.social #OncoAlertAF

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastati On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, for adult...

📌FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

www.fda.gov/drugs/resour...
@oncoalert.bsky.social #OncoAlertAF

📌 Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial

ascopubs.org/doi/10.1200/JC…
@oncoalert.bsky.social #OncoAlertAF

🌟Exploring neoadjuvant therapy for occult #BreastCancer with axillary presentation, a retrospective study of 114 patients suggests that targeted axillary surgery may be considered instead of axillary dissection in select cases. 🌟

Read more 👉 buff.ly/3Wfs9WI
#Oncology #OncoAlertAF

📌 Cancer in a drop: Liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024

sciencedirect.com/science/articl…

@oncoalert.bsky.social #OncoAlertAF

📌 CAR-T cell therapy for breast cancer: Current status and future perspective

sciencedirect.com/science/articl…

@oncoalert.bsky.social #OncoAlertAF

Dear colleagues,
Join us for the 5th #OncoAlert Colloquium! 🚨🌟
👉 buff.ly/3CChgre 👈

📅 February 3-9, 2025
🎟️ FREE Registration
📰one week covering the latest in oncology

Don’t miss this unique #oncology event! 🌍👩‍⚕️👨‍⚕️

@oncoalert.bsky.social #OncoAlertAF

📌 Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

ascopubs.org/doi/10.1200/JC…

@oncoalert.bsky.social #OncoAlertAF